Wuxi Biocity Biopharmaceutics Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Zhengwei Li

Jian Li

Shuhui Chen

Wenyuan Qian

Chundao Yang

Jie Li

Guoping Hu

Zhengxia Chen

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

Cheng Xie

Zhifei Fu

Guibai Liang

Jian Wei Li

Yang Zhang

Peng Li

Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.

Crystal form of Wee1 inhibitor compound and use thereof

A pyrimidopyrazolone derivative as a Wee1 inhibitor and use thereof in preparation of a medicament for treating Wee1-related diseases are described. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.

Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof

Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Macrocyclic compound serving as Wee1 inhibitor and applications thereof

The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee1, and includes an application of the compound in treating various types of tumors. 

1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II): 

Tyrosine kinase inhibitor and pharmaceutical composition comprising same

Growing community of inventors

Shanghai, China

Zhengwei Li